Clinical Trial Update: Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update for apatinib as third-line and later therapy in small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN